Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- The VIVA FoundationLate-Breaking Clinical Trial Results Announced at The VEINS 2026The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine through education and research, today announced results from the Late-Breaking Clinical Trials presented at The VEINS 2026 conference, held at...
- Vaxcyte, Inc.Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine CandidateVaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow, October 5, 2026 at 8:00 a.m. ET / 5:00 a.m. PT to present topline data from the OPUS-1 adult pivotal Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) and pneumococcal pneumonia.
- GajuraPremier Cleaning Expands Commercial Janitorial Services for Denver Schools, Warehouses and Medical FacilitiesPremier Cleaning, a commercial cleaning company serving the Denver metro area, today announced an expansion of its janitorial services program for specialized facility types, including educational facilities, warehouse and distribution centers, and medical offices and clinics.The expansion formalizes service offerings for facility categories that carry cleaning requirements a general commercial crew is not always equipped to meet. Schools...
- Proexpo Communications LimitedKexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in ChinaRecently, Kexing Biopharma (688136.SH) announced that its wholly owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), has received a Notice of Approval for Drug Clinical Trials from China's National Medical Products Administration (NMPA), authorizing the initiation of clinical trials of GB20, a proprietary investigational anti-TL1A monoclonal antibody for inflammatory bowel disease (IBD).Inflammatory bowel...
- Снижение массы тела на 19,3 % к 48-й неделе -- данные исследования фазы III препарата Olatorepatide, двойного селективного агониста ГПП-1/ГИП компании Hansoh, представлены на EASDМИЛАН, 3 октября 2026 г. -- С 28 сентября по 2 октября 2026 года в Милане, Италия, проходит ежегодная конференция ассоциации European Association for the Study of Diabetes (EASD). Разработанный компанией Hansoh Pharma двойной селективный агонист рецепторов глюкагоноподобного...
- VB Health Launches Public Seven-Part Supplement Quality StandardVB Health launches a seven-part supplement quality standard covering research, dosing, sourcing, U.S. manufacturing, testing and transparency.
- Ractigen TherapeuticsRactigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular DystrophyFirst clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a monogenic disease. Paired muscle biopsies reveal 3.5- to 5.3-fold increases in sarcolemmal utrophin expression,...
- CVS HealthAetna 2027 Medicare plans offer reliable, affordable access to care & member supportCompanies: CVS HealthPlans designed to provide member value and access to care: $0 copays on Tier 1 drugs and covered vaccines at in-network pharmacies* $0 copays for annual physicals, colonoscopies and mammograms at in-network providers $0 copays for annual Healthy Home Visit from a licensed Signify Health...
- Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company")...
- Edelson Lechtzin LLPMillstone Medical Outsourcing Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is ExposedNational class action law firm offers free, confidential case evaluations to individuals whose personal, financial, and health information may have been exposed in the Millstone Medical Outsourcing data breach. NEWTOWN, Pa., Oct. 2, 2026 -- Edelson Lechtzin LLP, a national...
- Edelson Lechtzin LLPAtlantic Digestive Specialists Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is ExposedNational class action law firm offers free, confidential case evaluations to patients whose personal and protected health information may have been exposed in the Atlantic Digestive Specialists data breach. NEWTOWN, Pa., Oct. 2, 2026 -- Edelson Lechtzin LLP, a national class...
- CaseBioscience® schließt sich einem Team an, das von ARPA-H bis zu 7,3 Millionen US-Dollar für die Weiterentwicklung der Lagerung von Zelltherapien bei Raumtemperatur erhältFORT COLLINS, Colorado, 3. Oktober 2026 -- CaseBioscience® gab heute seine Beteiligung an einem multidisziplinären Team unter der Leitung von Likarda bekannt, dem von der Advanced Research Projects Agency for Health (ARPA-H) im Rahmen ihres Programms „BioStabilization...